Results 211 to 220 of about 5,782 (258)

Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma. [PDF]

Curr Oncol
Pelland AA, Dumas M, Lemieux-Blanchard É, LeBlanc R, Côté J, Boudreault JS, Duquette D, Kaedbey R, Lalancette M, Larose F, Nikonova A, Pavic M, Shamy A, Roy J, Sebag M, Trudel S, Claveau JS.   +16 more
europepmc   +1 more source

Mechanically Spatio‐Chimeric Fibrin Assembly Enables Vascular‐Integrated Muscle Reconstruction for Volumetric Muscle Loss Repair

Advanced Materials, EarlyView.
SPARC (spatio‐chimeric, plasma‐based, anisotropic, and shear‐responsive construct) that integrates myogenic and vascular microenvironments within a single construct. The dual‐modulus matrix directs aligned myotube formation and endothelial network development, enabling a vascularized muscle implant that seamlessly anastomoses with host tissue and ...
Su Hyun Jung, Minjun Kim, Da‐Yoon Kim, Min Kyu Kim, Sieun Lee, Yoonhee Jin, Joo H. Kang   +6 more
wiley   +1 more source

A Tissue Factor Bi-Specific T-Cell Engager Provides Effective Targeting and Cytotoxicity Against Cervical Cancer Cell Lines. [PDF]

Int J Mol Sci
Lee KJ, Kim G, Seo B, Jeong SY, Kim HS, Cho HY, Park ST.   +6 more
europepmc   +1 more source

Virus envelope glycoprotein targeting bispecific T cell engager protects mice from lethal severe fever with thrombocytopenia virus infection. [PDF]

Cell Rep Med
Peng X, Wang W, Liang Y, Jian Y, Wei Q, Yang T, Wang C, Yin X, Du M, Shang H, Liu R, Wang X, Shang X, Gong N, Xu Y, Wang C, Cui N, Zhang L, Guo Y, Liu W, Zhang H, Li H.   +21 more
europepmc   +1 more source

Solution structure and synaptic analyses reveal determinants of bispecific T cell engager potency. [PDF]

Proc Natl Acad Sci U S A
Leithner A, Staufer O, Mitra T, Liberta F, Valvo S, Kutuzov M, Dada H, Spaeth J, Zhou W, Schiele F, Reindl S, Nar H, Hoerer S, Crames M, Comeau S, Young D, Low S, Jenkins E, Davis SJ, Klenerman D, Nixon A, Pefaur N, Wyatt D, Dushek O, Kasturirangan S, Dustin ML.   +25 more
europepmc   +1 more source

Targeting mutated KRAS by HLA-A*02:01 restricted anti-KRAS TCR-mimic CAR and bispecific T cell engager. [PDF]

J Mol Med (Berl)
Ebrahimi S, Lohnes BJ, Khan SA, Peipp M, Bockamp E, Klein C, Abken H, Wölfel C, Theobald M, Hartwig UF.   +9 more
europepmc   +1 more source

An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release. [PDF]

J Immunother Cancer
Gaspar M, Natoli M, Castan L, Rahmy S, Korade M, Kelton C, Mulgrew K, Huhn O, Rees DG, Sigurdardottir A, Lloyd C, Taylor JJ, Brailey PM, Dallaway L, Toloczko A, Giraldo N, Broggi MAS, Kunihiro A, Abhishek S, He Y, Rong Y, Eyles J, Ball K, Fitzgerald J, Hammond SA, Cemerski S, Dovedi SJ, Cobbold M.   +27 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

T-cell-engaging bispecific antibodies in cancer

The Lancet, 2023
T-cell-engaging bispecific antibodies (BsAbs) simultaneously bind to antigens on tumour cells and CD3 subunits on T cells. This simultaneous binding results in the recruitment of T cells to the tumour, followed by T-cell activation and degranulation, and tumour cell elimination.
Niels W C J, van de Donk, Sonja, Zweegman   +1 more
openaire   +2 more sources

T-cell–engaging Therapy for Solid Tumors

Clinical Cancer Research, 2020
Abstract T-cell engagers (TCE) are a rapidly evolving novel group of treatments that have in common the concurrent engagement of a T-cell surface molecule and a tumoral cell antigen. Bispecific antibodies and genetically engineered adoptive cell therapies, as chimeric antigen receptors or T-cell receptors, have similarities and ...
Maria de Miguel, Pablo Umana, Ana Luiza Gomes de Morais, Victor Moreno, Emiliano Calvo   +4 more
openaire   +2 more sources